AIM ImmunoTech (AIM) Stock: Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 9, 2026

Net buying: insiders sold $0 and bought $29K on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: +$29K net
CongressSTOCK Act, 180 days: None
Big funds13F, latest quarter: No large changes
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about AIM filings

Are insiders buying or selling AIM ImmunoTech Inc (AIM) stock?

Net buying: insiders sold $0 and bought $29K of AIM stock on the open market in the 90 days to Nov 9, 2026, according to SEC Form 4 filings. The largest was Equels, Thomas K (CEO & President), who bought $29K. The latest filing was on Nov 9, 2026.

Which members of Congress have traded AIM recently?

None. No member of Congress disclosed a AIM trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this AIM smart-money data?

This summary uses filings available on Nov 9, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

Smart money on AIM

Lean long1 source:
- Insiders

Top traders
No tracked positions at the last update
Insiders
Lean long3 buys · $10.2K
Form 4 filings, open market.
Politicians
No recent politician filings found
Funds
No recent fund filings found
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about AIM filings

Are insiders buying or selling AIM ImmunoTech Inc (AIM) stock?

Which members of Congress have traded AIM recently?

None. No member of Congress disclosed a AIM trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this AIM smart-money data?

Insiders

What insiders are doing

8 trades · 6 mo

Bought$29K

Buys (3)

ET
Equels Thomas K
CEO & President · Nov 9
$2K
bought
ET
Equels Thomas K
CEO & President · Nov 6
$3K
bought
ET
Equels Thomas K
CEO & President · Oct 26
$5K
bought

2 more trades

Pro opens all of them for $16.50/month, paid yearly.

Unlock all 2 trades

Unlock everything for $29/month

Unlock for $29/month

Reported Aug 7, 2026

Earnings came in $0.31 a share below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 7, 2026

Period ending

Jun 30, 2026

Earnings per share

-$0.43-$0.31 miss

-$0.12 expected

Revenue

$26.0K

SEC filing

Next report

Estimated report: Nov 16, 2026, in 7 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Jun 30, 2026Reported Aug 7, 2026	-$0.43est. -$0.12	-$0.31miss	$26.0KSEC filing	+4.0%from $25.0K
Mar 31, 2026Reported May 15, 2026	-$0.69est. -$0.37	-86.49%miss	$22.0KSEC filing	+37.5%from $16.0K
Dec 31, 2025Reported Dec 31, 2025	-$0.44est. -$0.94	+53.15%beat	$88.0K · FYSEC filing	No year-ago quarter
Sep 30, 2025Reported Nov 17, 2025	-$1.57est. -$0.98	-60.20%miss	$26.0KSEC filing	-25.7%from $35.0K
Jun 30, 2025Reported Aug 14, 2025	-$3.68est. -$7.99	+53.94%beat	$25.0KSEC filing	-50.0%from $50.0K
Mar 31, 2025Reported May 15, 2025	-$4.99est. -$7.99	+37.55%beat	$16.0KSEC filing	-60.0%from $40.0K
Dec 31, 2024Reported Mar 27, 2025	-$10.00est. -$0.09	-$9.91miss	$170.0K · FYSEC filing	No year-ago quarter
Sep 30, 2024Reported Nov 14, 2024	-$6.88est. -$8.66	+20.55%beat	$35.0KSEC filing	-23.9%from $46.0K

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $0.15
High: $0.16
Low: $0.15
Prev close: $0.15
52-wk high: $1.75
52-wk low: $0.15
Mkt cap: $6.2M
ROE: -2382.0%
Fwd P/E: 2.0x
Beta: 1.31
P/S: 65.1x
P/B: 0.8x
Profit margin: +0.0%
Op margin: -13512.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Forward P/E: 2.01
Market cap: $6M

Valuation

P/S65.09
P/B0.80

Quality

Operating margin-13512.0%
ROE-2382.0%
ROA-82.6%

Growth

Beta1.31

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

0 / 100

RSI 14

43balanced

20D volatility

54%annualized

52-week range

$0.15

$0.15$1.75

20D support

$0.15recent floor

20D resistance

$0.18recent ceiling

Returns

5D +0.3%20D -13.9%60D -40.1%

Price vs moving averages

SMA20 -5.0%SMA50 -18.5%SMA200 -66.3%

Volume pace

0.32xvs prior 20D

Smart money at a glance

Filings to Nov 9, 2026

Net buying: insiders sold $0 and bought $29K on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: +$29K net
CongressSTOCK Act, 180 days: None
Big funds13F, latest quarter: No large changes
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about AIM filings

Are insiders buying or selling AIM ImmunoTech Inc (AIM) stock?

Which members of Congress have traded AIM recently?

None. No member of Congress disclosed a AIM trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this AIM smart-money data?

Smart money on AIM

Lean long1 source:
- Insiders

Top traders
No tracked positions at the last update
Insiders
Lean long3 buys · $10.2K
Form 4 filings, open market.
Politicians
No recent politician filings found
Funds
No recent fund filings found
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about AIM filings

Are insiders buying or selling AIM ImmunoTech Inc (AIM) stock?

Which members of Congress have traded AIM recently?

None. No member of Congress disclosed a AIM trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this AIM smart-money data?

Insiders

What insiders are doing

8 trades · 6 mo

Bought$29K

Buys (3)

ET
Equels Thomas K
CEO & President · Nov 9
$2K
bought
ET
Equels Thomas K
CEO & President · Nov 6
$3K
bought
ET
Equels Thomas K
CEO & President · Oct 26
$5K
bought

2 more trades

Pro opens all of them for $16.50/month, paid yearly.

Unlock all 2 trades

Unlock everything for $29/month

Unlock for $29/month

Reported Aug 7, 2026

Earnings came in $0.31 a share below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 7, 2026

Period ending

Jun 30, 2026

Earnings per share

-$0.43-$0.31 miss

-$0.12 expected

Revenue

$26.0K

SEC filing

Next report

Estimated report: Nov 16, 2026, in 7 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Jun 30, 2026Reported Aug 7, 2026	-$0.43est. -$0.12	-$0.31miss	$26.0KSEC filing	+4.0%from $25.0K
Mar 31, 2026Reported May 15, 2026	-$0.69est. -$0.37	-86.49%miss	$22.0KSEC filing	+37.5%from $16.0K
Dec 31, 2025Reported Dec 31, 2025	-$0.44est. -$0.94	+53.15%beat	$88.0K · FYSEC filing	No year-ago quarter
Sep 30, 2025Reported Nov 17, 2025	-$1.57est. -$0.98	-60.20%miss	$26.0KSEC filing	-25.7%from $35.0K
Jun 30, 2025Reported Aug 14, 2025	-$3.68est. -$7.99	+53.94%beat	$25.0KSEC filing	-50.0%from $50.0K
Mar 31, 2025Reported May 15, 2025	-$4.99est. -$7.99	+37.55%beat	$16.0KSEC filing	-60.0%from $40.0K
Dec 31, 2024Reported Mar 27, 2025	-$10.00est. -$0.09	-$9.91miss	$170.0K · FYSEC filing	No year-ago quarter
Sep 30, 2024Reported Nov 14, 2024	-$6.88est. -$8.66	+20.55%beat	$35.0KSEC filing	-23.9%from $46.0K

Open: $0.15
High: $0.16
Low: $0.15
Prev close: $0.15
52-wk high: $1.75
52-wk low: $0.15
Mkt cap: $6.2M
ROE: -2382.0%
Fwd P/E: 2.0x
Beta: 1.31
P/S: 65.1x
P/B: 0.8x
Profit margin: +0.0%
Op margin: -13512.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Forward P/E: 2.01
Market cap: $6M

Valuation

P/S65.09
P/B0.80

Quality

Operating margin-13512.0%
ROE-2382.0%
ROA-82.6%

Growth

Beta1.31

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

0 / 100

RSI 14

43balanced

20D volatility

54%annualized

52-week range

$0.15

$0.15$1.75

20D support

$0.15recent floor

20D resistance

$0.18recent ceiling

Returns

5D +0.3%20D -13.9%60D -40.1%

Price vs moving averages

SMA20 -5.0%SMA50 -18.5%SMA200 -66.3%

Volume pace

0.32xvs prior 20D

AIM ImmunoTech Inc

Smart money at a glance

What do analysts expect?

Questions about AIM filings

Smart money on AIM

Questions about AIM filings

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in $0.31 a share below what analysts expected.

Estimated report: Nov 16, 2026, in 7 days

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

AIM ImmunoTech Inc

Smart money at a glance

What do analysts expect?

Questions about AIM filings

Smart money on AIM

Questions about AIM filings

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in $0.31 a share below what analysts expected.

Estimated report: Nov 16, 2026, in 7 days

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

AIM ImmunoTech Inc

Overview

Questions about AIM filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

AIM ImmunoTech Inc

Overview

Questions about AIM filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.